Her2
Entity.
- Evidence
- 179 documents · 53 separate publishers
- Standing
- A name from our starting list; its record is kept up to date automatically from coverage
- Time
- first seen 22 Mar 2026, last seen 2 Nov 2026
- Measured
- 8% of mentions say something specific about it; the rest only name it
- As of
- 3 Nov 2026
Where this comes from
- Tech Times · 2026-10-31 · HER2-Positive Breast Cancer Trial Reports 92% Survival in Chemo-Free Patients; Proof Pending (opens the source in a new tab)
- The ASCO Post · 2026-10-30 · TALENT Neoadjuvant T-DXd in HER2-Low Early Breast Cancer (opens the source in a new tab)
- 2 Minute Medicine · 2026-10-27 · Zanidatamab-hrii combinations improved survival in first-line HER2-positive advanced gastroesophageal adenocarcinoma (opens the source in a new tab)
- Endpoints News · 2026-10-26 · BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results (opens the source in a new tab)
- Clinical Trials Arena · 2026-10-25 · ESMO26: An $8.4bn bispecific ADC doubles PFS in HR+/HER2- breast cancer (opens the source in a new tab)
- PR Newswire · 2026-10-25 · 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer (opens the source in a new tab)
- European Medical Journal · 2026-10-22 · Earlier ESR1 m Detection May Help Delay Endocrine Resistance in HR+/HER2– Advanced Breast Cancer (opens the source in a new tab)
- medRxiv Oncology · 2026-10-22 · Adjuvant Trastuzumab Deruxtecan Versus Trastuzumab Emtansine by Residual Cancer Burden in HER2-Positive Early Breast Cancer: A Decision Analysis (opens the source in a new tab)
- medRxiv Oncology · 2026-10-20 · Nationwide HER2 Testing, Prospective Trastuzumab-Based Therapy, and Deep Visual Proteomics in Esophageal Squamous Cell Carcinoma (opens the source in a new tab)
- Frontiers Precision Oncology · 2026-10-16 · Endocrine resistance in HR+/HER2− breast cancer: molecular mechanisms and emerging therapeutic strategies (opens the source in a new tab)